medigraphic.com
ISSN 2225-4676 (Electronic)

2011, Number 1

<< Back Next >>

Rev Cubana Neurol Neurocir 2011; 1 (1)

Preliminary results of Nimotuzumab treatment in 3 patients with recurrent meningioma

Felipe MA, Casacó PA, Prince LJ, Cañizares MC, Pérez LP, Morales PI, Quintanal CN

Language: Spanish
References: 13
Page: 37-43
PDF size: 1629.12 Kb.


ABSTRACT

Introduction: Around 20% of all primary tumors of the brain are meningiomas. The recurrence rate of lesions seemingly in a total resection way is frequent, existing few studies that offer what to do after the surgery and the radiotherapy has not been effective.
Case report: They show up the results of the treatment of 3 patients with multiple recurrent meningiomas, operated in several occasions and without control of their illness, in which a high expression in immunohistochemical analysis of epidermal growth factor are present, reason why they decided to treat the patients with the monoclonal antibody Nimotuzumab (h-R3) in dose of 200 mg in 250 ml of saline isotonic solution during 30 minutes in vein, once weekly during 4 weeks and continuing later on every 21 days for the period of one year. Adverse, toxic, and allergic reaction wasn’t reported during the study interval. The 12 months progression free survival of illness was of 100%. A patient presented a quick and great relapse that couldn’t be resolved by surgery, after 6 months of ceasing the medication, dying in the later months.
Conclusions: Nimotuzumab is a treatment option for recurrent meningioma. The prolonged use of this is suggested.


REFERENCES

  1. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009;9:231–40.

  2. Alexioua GA, Gogoub P, Markoulac S, Kyritsis AP. Management of meningiomas. Review. Clin Neurol Neurosurg. 2010;112:177–82.

  3. Weber DC, Lovbladb KO, Rogersc L. New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Curr Op Neurol. 2010,23:563–70.

  4. Campbell BA, Jhamb A, Maguire JA, Toyota B, Ma R. Meningiomas in 2009: controversies and future challenges. Am J Clin Oncol. 2009;32:73–85.

  5. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM. Atypical and malignant meningiomas: a clinicopathological review. Neurosurg. 1993;33:955–63.

  6. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, et al. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Rad Onc. 2010;5:46–53. Disponible en: http://www.ro–journal.com/content/5/1/46 [06.09.2010].

  7. Wen PY, Yung W, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, et. al. Phase II study of imatinib mesylate (Gleevec®) for recurrent meningiomas (North American Brain Tumor Consortium Study 01–08) Neuro –Oncology. 2009;11:1–26.

  8. Pérez R, Lage A. Los factores de crecimiento y sus relaciones con la transformación maligna. Interferon y Biotecnologia. 1986;3:179–209.

  9. Cohen S, Carpenter G. Human Epidermal Growth Factor: Isolation and Chemical and Biological properties. Proc Natl Acad Sci USA. 1975;72:1317–21.

  10. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et. al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96:211–7.

  11. Ramnarayan K, Skaletsky E. Antibody humanization predicted by computer Graphic Analysis. Am Biotechnol. Lab. 1995;13:26–8.

  12. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3:71–81.

  13. Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, et al. Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study. Hybridoma. 2001;20:131–8.




2020     |     www.medigraphic.com